Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Schizophrenia
Interventions
DRUG

Pergolide

"0,3 mg pergolide (the first two days begin with 0,05mg, then increase of dose of 0,1mg every 3 days for a maximum of 0,3mg/d, taken orally 3x 0,1mg/day). Then stable dose of 0,3mg for one week.. Subsequently slow (for 8 days) reduction of dosage of 0,1mg every 3 days for 6 days then 0,05mg every day for the last two days.~Placebo group is identical in appearance and number of placebo capsules, in the same starting and maintenance scheme as for the pergolide group."

Trial Locations (4)

20246

Universitätsklinikum Hamburg - Eppendorf, Hamburg

69115

Psychiatrische Universitätsklinik, Heidelberg

76307

SRH Klinikum Karlsbad - Langensteinbach gGmbH, Karlsbad

Unknown

Zentralinstitut für Seelische Gesundheit, Mannheim

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

Heidelberg University

OTHER

NCT01066403 - Adjuvant Therapy With Pergolide in Treating Cognitive Deficits in Schizophrenia | Biotech Hunter | Biotech Hunter